Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.72 |
| ▸ | DRD2 | P14416 | 3/20 | 0.72 |
| ▸ | TLR4 | O00206 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | APP | P05067 | 1/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311917 | 1.00 | ADRB2 (0.72) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL4655898 | 0.88 | ADRB2 (0.81) | ADRB2DRD2TLR4MAPTDNM1 | |
| SCHEMBL14359319 | 0.88 | ADRB2 (0.78) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL1206988 | 0.87 | ADRB2 (0.87) | ADRB2DRD2TLR4MAPTDNM1 | |
| SCHEMBL1326738 | 0.87 | ADRB2 (0.74) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL29811211 | 0.87 | ADRB2 (0.91) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL194220 | 0.87 | ADRB2 (0.91) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL599530 | 0.86 | ADRB2 (0.89) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL15512534 | 0.86 | ADRB2 (0.89) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL600699 | 0.86 | ADRB2 (0.89) | ADRB2DRD2TLR4MAPTDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076047-A1 | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt | AUROBINDO PHARMA LTD (IN) | 2010-03-25 | — | — | US | claimed |
| US-20170119678-A1 | EXTENDED RELEASE COMPOSITIONS OF CARVEDILOL PHOSPHATE | HETERO RESEARCH FOUNDATION (IN) | 2017-05-04 | — | — | US | disclosed |
| US-8637080-B2 | Rupturing controlled release device comprising a subcoat | Osmotica Kereskedelmi és Szolgáltató, KFT (HU) | 2014-01-28 | — | — | US | disclosed |
| WO-2010092589-A2 | PROCESS FOR PREPARATION OF AMORPHOUS CARVEDILOL PHOSPHATE | ALKEM LABORATORIES LTD. (IN) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010089760-A2 | CONTROLLED RELEASE, MULTIPLE UNIT PHARMACEUTICAL COMPOSITIONS | ALKEM LABORATORIES LTD. (IN) | 2010-08-12 | — | — | WO | disclosed |
| US-20100076047-A1 | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt | AUROBINDO PHARMA LTD (IN) | 2010-03-25 | — | — | US | disclosed |
| US-20100076047-A1 | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt | AUROBINDO PHARMA LTD (IN) | 2010-03-25 | — | — | US | disclosed |
| US-20100076047-A1 | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt | AUROBINDO PHARMA LTD (IN) | 2010-03-25 | — | — | US | disclosed |
| EP-2114881-A1 | PROCESS FOR THE PURIFICATION OF CARVEDILOL OR ITS SALTS THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2009-11-11 | — | — | EP | disclosed |
| US-20090004229-A1 | RUPTURING CONTROLLED RELEASE DEVICE COMPRISING A SUBCOAT | OSMOTICA COSTA RICA SOCIEDAD ANONIMA (CR) | 2009-01-01 | — | — | US | disclosed |
| WO-2008105794-A1 | PROCESS FOR THE PURIFICATION OF CARVEDILOL OR ITS SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207726-A1 | Process for the purification of carvedilol or its salts thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076047-A1 | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885DRD2 1551/4885TLR4 2210/4885 |
| US-20080207726-A1 | Process for the purification of carvedilol or its salts thereof | ADRB2, ADRB1, REN | ADRB2 1/4885DRD2 634/4885TLR4 2563/4885 |
| US-20170119678-A1 | EXTENDED RELEASE COMPOSITIONS OF CARVEDILOL PHOSPHATE | RYR2, CALML3, ATP2A3 | ADRB2 13/4885DRD2 1394/4885TLR4 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.